Perry Siatis is Senior Vice President, Deputy General Counsel, a member of the executive leadership team, and a senior legal advisor and strategist for AbbVie’s global Legal Department. He is credited with negotiating highly successful global business deals, navigating complex government policy, and providing strategic legal guidance for multiple billion-dollar brands. In 2020, he led the legal strategy for the acquisition of Allergan, one of the largest acquisitions in pharmaceutical history.
Mr. Siatis began his career by practicing commercial and intellectual property (IP) litigation at DLA Piper LLP. He joined Abbott in 2005 as Counsel and progressed to Division Counsel, IP Litigation and later became Divisional Vice President and Section Head, IP Strategy. In January 2013, Mr. Siatis joined AbbVie where he served as Vice President, Biologic Strategic Development and Legal Regulatory where he strengthened the legal strategy surrounding AbbVie’s premier biologic and the world’s top selling drug. Prior to his most recent role, Mr. Siatis was the Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer.
Presently, Mr. Siatis is responsible for Legal Transactions, including M&A and licensing, Alliance Management and R&D Legal; Litigation, Legal Compliance and Regulatory; Intellectual Property and Strategy; Corporate Legal, Governance, and Operations; and Global Commercial Legal, including the Legal team for Allergan Aesthetics. He is a champion of diversity and inclusion and has spearheaded AbbVie Legal engagements with Historically Black Colleges and Universities and the National Association of Minority & Women Owned Law Firms.
Mr. Siatis earned a bachelor's degree in accounting from George Mason University and a Juris Doctorate degree from Brigham Young University.